Bio Green Med Solution, Inc. (BGMS): M&A transaction — Bio Green Med Solution sells Plogosertib assets to Tethra Biosciences for $300K upfront plus $170K milestone

Bio Green Med Solution, Inc.

Sold all patent rights and IP related to Plogosertib (PLK1 inhibitor) to Tethra Biosciences Inc.
Total consideration: $300,000 upfront plus a potential $170,000 milestone upon first patient dosing in Phase 2.
Transaction closed on October 6, 2025, with customary representations and warranties.
Buyer assumes obligations related to the Compound from closing forward; seller retains excluded liabilities.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Bio Green Med Solution, Inc. completed a disposition involving Tethra Biosciences Inc. for $300,000, plus a further potential Milestone of $170,000 (closed 2025-10-06).

Action: disposition
Counterparty: Tethra Biosciences Inc.
Consideration: $300,000, plus a further potential Milestone of $170,000
Closing: 2025-10-06

Exact text from the filing

of the Company related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies (“Plogo”), for a purchase price of $300,000, plus a further potential Milestone (as defined in the Purchase Agreement) of $170,000. The Purchase Agreement contains customary representations, warranties and covenants. The

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-017223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.